ESMO On Location Day 3

The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.

Judy E. Garber, MD, MPH, of the Dana Farber Cancer Institute is the recipient of the 2026 Basser Global Prize.

The European Commission approved T-DXd for patients with HER2+ breast cancer who have residual invasive disease after neoadjuvant treatment.

Elranatamab improved PFS vs 3 standard regimens in relapsed/refractory multiple myeloma in the phase 3 MagnetisMM-32 trial.

INCB161734 plus chemotherapy was tolerable and elicited responses in updated data from a trial of patients with KRAS G12D–mutated pancreatic cancer.

Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.

Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.

Rinatabart sesutecan significantly improved PFS and OS vs investigator’s-choice chemotherapy in platinum-resistant ovarian cancer.